



**Cancer Prevention and Control Central IRB**

**Meeting Agenda**

**Thursday, April 27, 2017  
9:00 am –11:05 am Eastern Time**

**Agenda**

---

**I. General Business**

- Next Meeting: Thursday, May 25, 2017
- 

**II. Reports for 03/01/17 – 03/31/17**

- CPC CIRB Local Context Subcommittee Report
  - Expedited Reviews and Study Acknowledgements
  - Study Activation Acknowledgements
  - Amendment Activation Acknowledgements
- 

**III. Review/Approval of Minutes**

- March 23, 2017
- 

**IV. Continuing Review**

**MDA2014-04-01**, Alternative Dosing of Exemestane in Postmenopausal Women with Stage 0-II ER-Positive Breast Cancer: a Randomized Presurgical Trial (Protocol Version Date 11/28/16)

---

**V. Continuing Review**

**MDA2013-02-02**, Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus with Radiofrequency Ablation (Protocol Version Date 12/02/16)

---

**VI. Continuing Review**

**UAZ2015-05-02**, M4OC-Prevent: Metformin for Oral Cancer Prevention (Protocol Version Date 09/30/16)

---

**VII. Study Chair Response to Tabled Initial Review**

**EA1151**, Tomosynthesis Mammographic Imaging Screening Trial (TMIST) (Protocol Version 04/04/17)

---

**VIII. Study Chair Response to Tabled Initial Review**

**MDA2016-07-02**, A Randomized, Double-blind, Placebo-controlled Study of 4-hydroxytamoxifen Topical Gel in Women with Mammographically Dense Breast (Version 5, Protocol Version Date 04/06/17)

---

**IX. Amendment Review**

**A221504**, A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer (Adenocarcinoma) (Protocol Version 02/28/17)

---